| __timestamp | BioCryst Pharmaceuticals, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 51796000 | 21226345 |
| Thursday, January 1, 2015 | 72758000 | 87718074 |
| Friday, January 1, 2016 | 61008000 | 93831530 |
| Sunday, January 1, 2017 | 66962000 | 79419009 |
| Monday, January 1, 2018 | 84888000 | 132166913 |
| Tuesday, January 1, 2019 | 107068000 | 89124838 |
| Wednesday, January 1, 2020 | 122964000 | 65782137 |
| Friday, January 1, 2021 | 208808000 | 88845513 |
| Saturday, January 1, 2022 | 253297000 | 134715000 |
| Sunday, January 1, 2023 | 216566000 | 180142000 |
Cracking the code
In the competitive world of biotechnology, strategic investment in research and development (R&D) is crucial for innovation and growth. Over the past decade, Intra-Cellular Therapies, Inc. and BioCryst Pharmaceuticals, Inc. have demonstrated distinct approaches to R&D spending. From 2014 to 2023, BioCryst Pharmaceuticals increased its R&D expenses by approximately 318%, peaking in 2022. In contrast, Intra-Cellular Therapies saw a more modest increase of around 748% over the same period, with a significant surge in 2023. This divergence highlights BioCryst's aggressive push in recent years, while Intra-Cellular Therapies has shown a steady commitment to innovation. These trends underscore the importance of strategic R&D investments in driving biotech advancements and maintaining competitive edges in the pharmaceutical industry.
Research and Development Investment: Zoetis Inc. vs Intra-Cellular Therapies, Inc.
Research and Development Expenses Breakdown: argenx SE vs Intra-Cellular Therapies, Inc.
Comparing Innovation Spending: Teva Pharmaceutical Industries Limited and BioCryst Pharmaceuticals, Inc.
Research and Development Investment: Genmab A/S vs Intra-Cellular Therapies, Inc.
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Opthea Limited
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Apellis Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amicus Therapeutics, Inc.
Intra-Cellular Therapies, Inc. or Celldex Therapeutics, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.
R&D Insights: How Grifols, S.A. and BioCryst Pharmaceuticals, Inc. Allocate Funds
Protagonist Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Celldex Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.